Good morning everyone, here in Darmstadt at the Merck Innovation Center and from Darmstadt into the world, and a warm welcome to our annual Merck press conference. My name is Axel Löbel, I'm Head of Communications of Merck, and I'm here today with our CEO, Belén Garijo, and our CFO, Helene von Roeder, and both will walk you through our results of 2025 and, of course, talk about our outlook for 2026.

As always, both Helene and Belén will give some insights first before we dive into our Q&A session a little bit later. With that already, I'd like to ask to the stage Belén Garijo.

Belén, the stage is yours.

Thank you, Axel, and good morning, everyone. Thank you for taking part in our full-year press conference, whether you are here in Darmstadt or following us virtually.

As Axel mentioned, Helene and I will provide an overview of our business performance for 2025 as well as an outlook for 2026. After this, we look forward to your questions.

Let me start by summarizing 2025 in a few messages. We delivered on our financial guidance.

Second, our diversified business and regions was a source of strength. Last but not least, we are positioned in major growth areas, such as health and AI, and this will be a strong platform for future growth.

Before we dive into the numbers, let me reflect on 2025. We recognize that the ongoing crisis, the geopolitical tensions, and rather global challenges have become the new normal, our new reality.

The recent developments in the Middle East once again demonstrate how quickly political uncertainties can escalate. This is obviously a very concerning situation, and as you can imagine, the safety of our employees and the safety of our partners in the region is a top priority for us right now.

We are in close contact with our teams on the ground, and at this moment, we see no material impact both at the employee level or in anything that relates to our logistics and distribution. Now, let us deep dive now on 2025.

Our achievements are made possible by our more than 62,000 dedicated colleagues globally and our recently expanded executive board team. I want to take this opportunity to extend my heartfelt gratitude to the entire Merck team for their commitment, for their creativity, and for their dedication.

Thank you so much, everybody. In 2025, as we strengthened our executive board, welcoming Danny Bar-Zohar, Jean-Charles Wirth, and Khadija Ben Hammada to the team.

We also announced that Kai Beckmann will be my successor as the CEO of Merck. Most recently, Benjamin Hein has been appointed as Kai's successor as the CEO of Electronics.

Let me now highlight some of our business sectors in 2025. First, in Life Science, we continued to invest on both capability and capacity.

In 2025, we opened our new €100 million facility in Blarney in Ireland, and this site produces critical filtration technologies that are used in advanced therapies and is expected to create over 200 jobs by 2028. We are also strengthening our innovation capabilities, including in the next-generation biology.

This is illustrated through the strategic acquisitions that we have announced as Hub Organoids and the JSR chromatography business in Life Science. Those are excellent examples of how we are reinforcing our portfolio leadership strategy.

Organoids provide earlier predictive insights into human biology and help researchers identify promising candidates faster and make better-informed decisions when it comes to clinical development. Of course, this leads to faster clinical progress and, hopefully, to improved outcomes for complex diseases like cancer as well as genetic disorders.

You can see an organoid 3D dome as an exhibit here. Now, in the healthcare sector, we are making strategic moves to strengthen our position in high-growth areas.

In July 2025, we completed the acquisition of SpringWorks in the US, establishing rare diseases as a new strategic growth pillar for Merck. In October, we announced an agreement with the White House to increase access to approved IVF therapies.

This will strengthen our presence in this highly attractive market while providing affordable access to innovative fertility treatments to families on their journey to parenthood. You will also see Pergoveris pen, one of our key IVF treatments, in today's exhibit.

In December, we received an approval for pimicotinib in China for treating symptomatic tenosynovial giant cell tumor, which is a rare tumor that affects joints, tendons, or the bursae. This is [Pimi's?]

first global approval and a significant step in strengthening our leadership in rare tumors, which will stay a key growth drivers for us. Now, let's look at Electronics.

In 2025, we seized new opportunities for our electronic business and gained benefit from the growing artificial intelligence demand. In August, we also completed the sale of Surface Solutions, allowing Electronics to become a pure-play business in semiconductor solutions.

At the end of 2025, the acquisition of Unity SC already contributed to our organic growth for the first time since we acquired the company. In December, we also inaugurated a €500 million Semiconductor Solutions megasite in Taiwan.

Therefore, Electronics is well-positioned to meet the rising demand from artificial intelligence. It is important to note that Merck is involved in 99%, yes, 99% of chips that are produced worldwide.

We supply materials and chemical solutions for many of the critical steps in chip manufacturing process. In our exhibits today, you can see three different types of transistors that are essential for chip production.

To give you an idea of scale, the Apple M1 Max chip contains approximately 57 billion transistors, all packed into an area about the size of the tip of an index finger. The technologies and services that we offer to the semiconductor industry are one of Merck's key growth drivers.

Let me now give you an example of how Merck delivers on future technologies, because as a science and technology company, we drive innovation by bringing technologies together. A great example is our partnership with Imec on organ-on-a-chip technology, which combines our expertise in biology with advanced semiconductor chips to simulate human organ functions using living cells.

This allows scientists to test medications safely and effectively without using animals, making also drug development faster and even more reliable. You can see this technology, once again, among our exhibits today.

All these achievements demonstrate what I said at the beginning, and this is our strategy to drive growth through innovation is working. Our diversified businesses and regions is giving us significant resilience and strength.

Our in-region, for-region approach provides global flexibility while meeting local needs. We are well-positioned in major growth areas also for the future, and those are semiconductors, rare diseases, and advanced therapies.

Today, Merck stands strong with a clear focus on three growth drivers: Process Solutions in Life Science, rare diseases in Healthcare, and Semiconductor Solutions in Electronics. This is, once again, a strong platform for future growth.

Now, let's move on to the financial performance of 2025 that Helene will further detail. We have delivered on our guidance spot-on despite a tough 2025 that was marked by significant geopolitical challenges in major markets and, importantly, very strong currency headwinds.

Net sales were around stable at €21.1 billion, and throughout the year, strong negative foreign exchange effects weighed on net sales and EBITDA pre. These effects largely resulted from the exchange rate development of several Asian currencies as well as the US dollar.

Overall, the group EBITDA pre was €6.1 billion, up by 5.6% organically. Now, let's look briefly at some of the highlights from Q4 of 2025.

In Q4 2025, our group organic sales came in at a solid 2.6% growth. We delivered profitable growth once again, supported by all the three sectors, with group EBITDA pre up 3.1% organically.

In Life Science, strong order intake momentum in Process Solutions fueled the growth in the business sector. The organic sales growth in Healthcare was driven by strong growth in our CM&E franchise alongside contributions from Mavenclad and from fertility.

Both Mavenclad and Pergoveris achieved double-digit growth. Although Electronics reported a decline in organic sales due to headwinds from our DS&S business, our semiconductor materials business achieved its strongest quarter of the year in Q4.

It continued to benefit from strength in artificial intelligence and the advanced nodes markets. Based on this result, we will propose a stable dividend of €2.2 during our annual general meeting in April 24th.

Now, let's take a closer look at the numbers for the full year 2025, and it's my pleasure to hand over to Helene who will walk you through our 2025 financial performance. Helene, welcome on the stage.

Thank you very much, and a warm welcome also from my side. If you look at our net sales in '25, they came in around stable, and our organic sales growth was really dampened by foreign exchange effects of around 4%.

Foreign exchange had a significant negative effect across all sectors, mainly driven by the US dollar as well as Asian currency. Our Life Science business, if you look at it, grew organically, driven by sustained demand from our Process Solutions customer that drove order momentum.

Healthcare delivered solid organic performance despite market pressures. Electronics recovered towards the end of the year thanks to AI-driven demand in our Semiconductor Solutions, although full-year organic sales were slightly down.

EBITDA pre was €6.1 billion, which actually corresponded to a margin of 28.9% of net sales. With that, let's take a look at our business sectors, and I'm starting with Life Science.

Life Science has returned to growth, delivering organic sales growth of 4%. As mentioned earlier, this growth was driven primarily by double-digit organic growth of our Process Solutions business that saw the market normalize and move beyond the destocking phase finally this year.

EBITDA pre rose 3.9% on an organic basis, but due to foreign exchange effects, EBITDA pre remained around stable at €2.6 billion. Now, despite the challenging environment, the EBITDA pre margin remained stable at 28.8%.

What we have seen is slightly higher R&D expenses as well as ramp-up costs for recent site expansions, which reflect our increased investment in innovation. This investment is absolutely crucial as it serves as a key driver for our future growth and differentiation in the market.

Moving on to Healthcare. Net sales in this sector climbed 3.7% organically.

Foreign exchange effects, however, had a negative impact of 4.1%. Growth was primarily driven by our CM&E franchise, which grew a stellar 7%, as well as strong contributions from our multiple sclerosis treatment, Mavenclad, and fertility treatment, Pergoveris.

As Belén just mentioned, we announced an agreement with the White House in October to enhance access to approved IVF treatment from EMD Serono. Our complete fertility portfolio has been available since beginning of February 2026 on trumbrx.gov and the new fertility instant savings website.

Of course, in the US, we are working towards approval of Pergoveris, a fertility medication already available in 75 countries. All in all, EBITDA pre came in at €3 billion for the business, which is up more than 11% organically.

Once again, foreign exchange effects partially offset the strong organic growth. With that, let's look at the Electronics sector.

Now, Electronics experienced a slight organic decline of 0.6%, which was mainly driven by our DS&S business caused by prolonged delays to large customer projects. Merck expects DS&S to stabilize in '26 and to return to growth in the medium term.

Despite this temporary headwind, our semiconductor materials business remained the main growth driver for Electronics. It delivered strong, high-single-digit organic sales growth for the year thanks to increased demand for high-value materials that enable AI chip systems and advanced nodes.

Advanced nodes refer to the latest semiconductor manufacturing processes, allowing for smaller feature sizes and the development of the most powerful chips. EBITDA pre was 9% lower, mainly due to one-time adjustments we reported in the second quarter of '25, as you may remember.

With that, let's take a look at our guidance for '26. Before I share the '26 guidance, note that there are three key assumptions underlying this guidance.

First, regarding portfolio changes, our forecast reflects the SpringWorks acquisitions as well as the Surface Solutions divestment. Both of those will show portfolio effects in the first half.

They will contribute to organic performance in the second half. Second, product scope.

This guidance assumes no sales in the US of Mavenclad from March '26 onwards amid generic competition. What it also excludes is the positive effects from a potential US launch of Pergoveris.

Third, my favorite topic, currencies. We expect a more volatile foreign exchange environment again in '26, and we assume negative FX effects to continue.

Of course, the main drivers are US dollar developments, but we also observe various Asian and emerging market currencies extremely volatile. With the evolution of currencies, please bear in mind that we expect for Q1 a disproportionate headwind coming from currencies relative to our full-year FX guidance.

Now, with these three underlying assumptions in mind, we are expecting group net sales of between €20 billion and €21.1 billion, which is based on an organic sales development of -1% to 2%. Group EBITDA pre of between €5.5 billion and €6 billion.

With that, let me walk you through the sector breakdown for '26. Starting with Life Science, our largest business, we confirm mid-single-digit organic sales growth.

That is very much in line with our projections from our Capital Markets Day, which was held in last October. We include in our assumption the continuation of the strong performance in our Process Solutions business.

Across Advanced and Discovery Solutions, we anticipate gradual improvements in biotech funding and academic research stabilization as well as in an evolving market environment in China. With that, moving on to Healthcare.

There, a challenging year is ahead of us amid lifecycle challenges for key brands, and that is in particularly Mavenclad. On the other hand, we expect growth in the remainder of the portfolio, including CM&E, fertility, and above all, the rare diseases, which will become, as Olli already said earlier, organic in the second half of '26.

For Electronics, we anticipate continued strong growth in our semiconductor materials business while our DS&S business stabilizes going forward. With that, I would like to hand it back for Belén for her closing remarks before we take your questions.

Thank you, Helene. Let me first summarize our results and highlights on what 2025 has truly shown us.

In the face of a multitude of challenges, we have delivered on our guidance. We also demonstrated our strength of our diversified strategy across businesses and regions, and we believe we are sitting a strong platform and in the right growth areas: semiconductors, artificial intelligence, rare diseases, advanced therapies, which, as I have said before, are strong platform for future growth.

This was not by any chance. It was the result of a strategy built to endure and to build a resilient team that consistently delivers.

As many of you mentioned to me at the beginning of the meeting, today is my last press conference with Merck. When I joined Merck in 2011, the company had just begun an unprecedented period of transformation.

You may remember those days. I do.

Alongside major acquisitions like Sigma-Aldrich and Versum, I took on the task of transforming our Healthcare business for a new era of patient care. When I became CEO in 2021, none of us could have imagined the volatile world we would have to navigate together.

A global pandemic, remember, I call myself a COVID CEO, the artificial intelligence revolution, and the geopolitical fragmentation reshaping entire industries. Through it all, Merck just not only survived, but I believe we also thrived.

We shifted from growth driven by acquisitions to disciplined capital-efficient growth. Today, our earnings are rising faster than our sales.

Our leverage is failing, and our every euro is working harder. The numbers tell the story.

We invested over €7 billion in more than 30 new and expanded sites worldwide. We deployed over €4 billion in strategic acquisition and divestments, and we didn't just weather the storm, we emerged stronger.

I am absolutely confident that Merck will continue this successful trajectory under Kai's leadership. Why?

Because Merck is very well-prepared and have very solid foundation for the next growth cycle. We have proven we can execute with discipline.

We bridge the physical and the digital world. We turn science into solutions that matter for patients and customers.

We know that the future belongs to those companies that can navigate complexity and deliver results. This is exactly what our company does and will continue to do.

I want to use this opportunity as well to say a heartfelt thank you to our teams around the world and, of course, to the executive team that has been working with me in recent years. To you, thank you for covering our story, thank you for holding us accountable, and thank you for your trust.

Overall, thank you for the journey. With this, Helene and I are ready for your questions.

Over to you, Axel.

Thank you, Belén. We are now transitioning into our Q&A sessions.

As always, we will start here in the room. Please raise your hand once I've called your name.

Please unmute yourself on the microphone in front of you, and we are happy to take your questions. For all journalists online, please use the Microsoft Teams link you have received from us in advance, raise your virtual hand, and again, once I've called your name, please unmute yourself and, if possible, turn on your camera.

We have now three chairs. I suggest we use them, so, Helene, if you would like to join us on stage again for the Q&A session.

I see already, and I knew it, one hand up from Sonja Wind from Bloomberg. Sonja, please go ahead.

Thanks for taking my question. I would be curious what you think about some analyst comments who said that Merck gave a deliberately conservative guidance because of the early Mavenclad, that it's not included from March on, and also Pergoveris, that it's not included in the guidance.

Do you agree with that assessment? Is there more upside for earning upgrades if all goes well?

My second question would be on the deal with Trump on the drugs. Can you give a bit more color on what is the size of that financial impact on the earnings?

How much does it matter, because it's only a certain patient group? Thank you.

Sonja, the agreement with the US administration, you mean? Where is the impact?

I will take this. Perhaps you want to start with the guidance.

I'll do that. Overall, what do we guide?

We guide to things that we have under our control and that we can actually see and predict properly. Pergoveris, we are in discussions, we are talking, but it's unclear exactly how that will shape.

I'm sure Belén will say that in a second. Mavenclad, again, the problem is we don't know how many generics will come, when, and at what point in time.

As a result, this is a guidance which reflects our current knowledge at this point in time, as it should, really.

For the agreement of the US administration, we have signed two agreements, and we believe that this is a real win-win-win. It's a win first for the patients who are going to have access to IVF at affordable prices.

It's a win for the administration because with our agreement, they have been able to also start this novel approach through the Trump Rx to sell directly to patients. It's a win for the company because we were already offering our treatments through different channels, and financially there is not a huge impact under the agreement.

The second agreement is the one that is going to make us exempt of tariffs for pharmaceuticals during 3 years. With this, you can imagine that we are extremely satisfied with the agreement, and we are actually hoping that as part of this agreement, we will also get the approval for Pergoveris in the US at some point in time in 2026.

Thank you. The next question comes also here from the room from Patricia Weiss from Reuters.

Patricia, please go ahead.

Good morning and thank you. Some questions around Mavenclad.

The strong effect comes something of a surprise even though the patent loss was known. Why no sales at all in the US instead of fewer, and how much of the €1.2 billion in last year was in North America?

What is the higher burden this year, forex or Mavenclad? It's your main product in Healthcare, what does that mean for the division, and which successor candidates are ready to fill this gap?

Thank you.

Maybe I start with the Mavenclad question and Belén will take the successor candidates, etc. Yes, roughly 50% of the sales in Mavenclad were US with 50% roughly in Europe.

At this point in time, when we look at the US, we have a number of generics lining up. They could be starting to sell tomorrow.

As a result, this is how we look at our guidance, to basically say we don't exactly know when the sales are going to start and how it's going to impact our sales. I think when you look at the guidance, this is basically how we see the world going forward, I don't think I need to add anything around that.

Maybe, Belén, you want to do the successor products?

I mentioned already the acquisition of SpringWorks has given us a new growth pillar. SpringWorks will contribute to organic growth, as Helene mentioned, as of the second half of 2026.

If you take the portfolio impact of the SpringWorks acquisition is already pretty nice, and it's contributing 5% of portfolio growth already. We are confident that SpringWorks will bring Healthcare to the mid-term guidance that we have communicated before progressively with 2026 being a year of transition in relation to the Mavenclad loss of exclusivity in the US.

Thank you. Patricia, does it answer all your questions?

Perfect. We don't have a question online yet, and here from the room, I see a question over there.

Please unmute yourself, from Weiyi Shan.

Hello, thank you for taking my question. I'm Weiyi Shan from Xinhua News Agency, and I'd like to ask a question about the global investments.

Due to the rising geopolitical tensions, and you have already mentioned about the agreements with the US administration, I would like to ask about whether you are considering a change in any other investments or strategic focus in any other markets like the Europe or China? Thank you.

Absolutely. We have mentioned several times our significant investment in our region-for-region approach, and this includes all the major regions.

Keep in mind that our main source of revenue already for the group is coming from Asia-Pacific, and of course, this is a very important growth avenue for Merck. We will continue to operate in this geopolitical context very much as a global company, but with a region-for-region approach.

Thank you. We have a question from an online participant, we have Bert Fröndhoff from Handelsblatt.

Please unmute yourself,

and

here we see you. Good morning.

I hope you can hear me too. Thank you for taking my question.

Just a quick one. I'm a bit confused about the issue of the US tariffs.

Did Merck pay tariffs on imports into the US in 2025? If so, will you demand a refund and take legal action to get it?

We are not thinking about refunds, the situation of tariffs in the US, as you may know, has recently changed with the Supreme Court decision, but this is not changing or having an impact on the agreement that we have signed with the US administration that I mentioned already. For 2025, do you want to comment?

Yeah.

As pharma tariffs under the Annex 2 were exempt, we didn't pay any tariffs in the pharma area. However, there were products in the Life Science area which were not exempt, we did pay tariffs in '25, and also small imports that we've seen in Electronics which were subject to tariffs.

As Belén just said, I'm not sure how the refund regime will be on the back of the Supreme Court, definitely nothing to be put in any guidance short-term. Then let's see how exactly the world pans out now post the recent announcements, Supreme Court, etc.

That one at the moment, it's pretty unclear how this will be.

Our agreement is basically out of this Supreme Court decision, it holds.

Yeah. Thank you.

Thank you. Thank you for the question, Mr.

Fröndhoff. I'm looking into the room.

Do we have further questions here from the live audience in Darmstadt? Anja Ettel from Die Welt.

Anja, please go ahead. Yes,

just to bridge the time gap, just a personal question for you, Belén Garijo. Looking back, what's the most important task that you achieved here at Merck, and what would you have liked to see unfold, but now you lack the time because you're leaving?

Thanks. I think I have been privileged to work with this company for 15 years.

I still remember my times in Healthcare, and we need to remember that, as I mentioned, when I came in 2011, we were starting an unprecedented transformation and the turnaround of Healthcare. In 2017, we launched three products to the market: Mavenclad, Bavencio, and Tepmetko.

If you look at how we refocus on pharma to be able to diversify the company, I feel very proud that I supported that transition actively from Healthcare to find this globally diversified business that I find in 2021. I feel particularly proud of everything that we have done on culture, talent, and people.

Of course, the financial performance that we have delivered is stellar, because if you look at the period between 2020 and 2025, our business revenues grew by 20%, our earnings grew faster, and our debt has been going down. Of course, there are many other things that we could have done, but if you look at the overall picture, I feel extremely proud of what we have achieved together in the last 15 and even 5 years.

Because Belén is very humble, you're looking at a CEO who has steered a company through unprecedented volatility in a very safe way. Actually, if you look at how we're set up now for the future, especially on the back of our local-for-local strategy, immunizing us from all of these geopolitical changes, that is a real feat.

I think we're all here at Merck super grateful for everything that Belén has done.

Thank you, Helene.

Thank you. We have a follow-up question, Sonja from Bloomberg.

Sonja, please go ahead.

Yes, my question is about the strategic review in the CDMO business. How is that progressing, and what is your plan there?

Go ahead. It's future-looking.

We are looking at all the options, and we will communicate once a decision is made. Clearly, this is what we can say today.

I don't know if you want to comment.

No, I think it's ongoing. We've announced clearly that we're looking at this.

You'll get news if they're ready to be announced.

Thank you. Tanja Feder, please go ahead.

Tanja? Yeah.

Thank you.

Microphone.

Thank you for taking my question. Just one task didn't succeed.

It was a deal for the Life Science business. Is this a task for your successor, Mr.

Beckmann, now? Or do you step away from this and

push it? You will hear from Kai what is the agenda.

I'm confident that the focus on Life Science will stay, because Life Science is our most important business. I would really wait to hear directly from Kai because he's the one that will be in charge as of May 2026.

Thank you. Do we have further questions here in the room?

Looking left and right. There's a bit of an overweight from questions from that side.

If not, also online we don't have any questions. Maybe last call.

Oh, we have a question from Focus Money from Julia Diong. Please unmute yourself and turn on the camera.

We can see you. Good morning.

Hi, good morning. I have one question concerning healthcare.

The last few weeks, we have seen very conflicting messages from from the FDA, to say the least, especially concerning rare diseases. First questions, how have Merck's interactions with the FDA been through the last months months?

Second questions, more broadly, what does it mean for for the healthcare business if somehow goalposts are moving and there there are new regulations concerning how a study has to be done or how many studies have to be done? Thank you.

We are very close to the regulatory agencies, not only to the FDA and particularly to the FDA, because, of course, as part of that agreement that I mentioned before, we are having discussions on the fertility franchise and other products. Overall, I see some of the news coming from the FDA as positive if at the end confirm that they will be a bit more open to grant approval with less studies or with a lower I don't think they will lower the bar anyway for the evaluation of risk-benefit of any new drug.

In particular, just to be brief, on orphan drugs, we are confident that this is the environment in which we can expect not only support from the regulatory agencies, but also encouragement to continue to invest and investigate new solutions for patients given that orphan drugs and rare diseases are huge unmet medical needs.

Thank you.

Thank you. Looking into the room, and we have a question from Ralph Heidenreich from Darmstädter Echo.

Ralph, please go ahead.

Yes, hello, thank you. Good morning.

First question is the personal question to Belén Garijo. Have you been surprised becoming the next CEO of Sanofi?

I would like to know your plans for the headquarters in Darmstadt. I think your last big investment program is over or will be over the next time, I'm not sure.

What will be next in Darmstadt? I would like to know your plans for the employees in Germany and in Darmstadt.

Look,

we are highly committed to Darmstadt. We have been investing in the last decade a significant amount of billion here.

This is our heart quarter. We repeat and repeat that because this is very important to us, we have given good signals of this.

Our plan for Darmstadt that you will have to further discuss for future years with my successor, I don't know if you want to comment, but is to continue to make sure that becoming a global company, we operate our company from our heart quarter. As for my personal question, I always said I keep all my options open, and that's the only thing I can continue to repeat.

Maybe I take a little bit on the Darmstadt. We continue to invest.

You see the number of construction cranes if you walk around the site. We raise our focus on bringing more business into Darmstadt.

Now I will do something slightly mean, because we also need German politicians and German politics to finally deliver on the simplification agenda. It is very clear that we are frequently faced with the discussion around can we put things here into Germany, which we really want, Belén said, heart quarter.

Then if you actually look at the delays around getting permissions at the entire red tape that we have in Germany, it is not helpful. If you could maybe include a big plea from our side, please deliver on the simplification, that would be great.

Thank you. Looking online, we don't have a question online.

Into the room, further follow-up questions here from the audience? Maybe one last check.

See a lot of smiles, but no raised hands, also not online. I would say this concludes our press conference this year.

A big thank you to all of you joining us here in Darmstadt today. Also big thank you to everyone online for joining us virtually.

I'm looking forward to seeing all of you during our annual general meeting on April 24th, live and in color from Frankfurt from Jahrhunderthalle, and of course, to our Q1 webcast on May 13th online as always. Please take care, see you soon, and all the best.

Thank you.

Thank you.